Medicines Transparency Alliance (MeTA) : country progress and key lessonsMeTApresents
This presentation shares the progress to date of the pilot phase of the Medicines Transparency Alliance (MeTA) and was given by Wilbert Banneberg, Technical Director of the International MeTA Secretariat at the launch of MeTA Jordan in May 2009
A critical assessment of health care purchasing in Tanzania: a comparison of ...resyst
This presentation was given at the International Health Economics Association (iHEA) World Congress in Milan, in July 2015. It includes results and policy implications from the RESYST Purchasing Study conducted Tanzania.
Medicines Transparency Alliance (MeTA) : country progress and key lessonsMeTApresents
This presentation shares the progress to date of the pilot phase of the Medicines Transparency Alliance (MeTA) and was given by Wilbert Banneberg, Technical Director of the International MeTA Secretariat at the launch of MeTA Jordan in May 2009
A critical assessment of health care purchasing in Tanzania: a comparison of ...resyst
This presentation was given at the International Health Economics Association (iHEA) World Congress in Milan, in July 2015. It includes results and policy implications from the RESYST Purchasing Study conducted Tanzania.
Sustainability and Transition Policy in Action (GF Session) - Tural Gulu, Az...OECD Governance
This presentation was made by Tural Gulu, Azerbaijan, at the 2nd Health Systems joint Network Meeting for Central, Eastern and Southeastern European Countries held in Tallinn, Estonia, on 1-2 December 2016
A critical analysis of purchasing mechanism in China's Rural Health Insurance...resyst
This presentation was given at the International Health Economics Association (iHEA) World Congress in Milan, in July 2015. It includes results and policy implications from the RESYST Purchasing Study conducted in China.
Section27 Health Reform Brief 1 July 2013Section 27
SECTION27 is proud to launch its Health Reform Briefs in an effort to broaden discussion about the different ways in which the health sector is changing. The briefs will look at reform in the health care sector through the lens of the Constitution and public interest, tying together economics, health systems theory and the law.
The first edition focuses on the design of NHI pilots. These briefs will be published every six weeks or so. If you would like to continue receiving these briefs, please send an email to: info@section27.org.za. And please share widely with others you think might be interested.
Good Governance for Medicines in JordanMeTApresents
Presentation by the Director General, Jordan Food and Drug Administration (JFDA) on ' Good Governance for Medicines in Jordan', during the World Health Assembly (WHA) in Geneva, 19 May 2009.
This presentation by the US Federal Trade Commission was made during a workshop on “Regulation and competition in light of digitalisation” held by the OECD in Paris on 31 January 2018. More papers and presentations on the topic can be found out at oe.cd/wrcd.
Interventions that fail to sustain: Evidence from a training and certificatio...ILRI
Poster by Charity Kinyua, Silvia Alonso, Emma Blackmore and Vusilizwe Thebe presented at the virtual Agriculture, Nutrition and Health (ANH) Academy Week 2021, 29 June – 1 July 2021.
Presentation by Dennis Ross-Degnan on tools and approaches that can be used by countries involved in the Medicines Transparency Alliance (MeTA), at the London launch in May 2008
Sustainability and Transition Policy in Action (GF Session) - Tural Gulu, Az...OECD Governance
This presentation was made by Tural Gulu, Azerbaijan, at the 2nd Health Systems joint Network Meeting for Central, Eastern and Southeastern European Countries held in Tallinn, Estonia, on 1-2 December 2016
A critical analysis of purchasing mechanism in China's Rural Health Insurance...resyst
This presentation was given at the International Health Economics Association (iHEA) World Congress in Milan, in July 2015. It includes results and policy implications from the RESYST Purchasing Study conducted in China.
Section27 Health Reform Brief 1 July 2013Section 27
SECTION27 is proud to launch its Health Reform Briefs in an effort to broaden discussion about the different ways in which the health sector is changing. The briefs will look at reform in the health care sector through the lens of the Constitution and public interest, tying together economics, health systems theory and the law.
The first edition focuses on the design of NHI pilots. These briefs will be published every six weeks or so. If you would like to continue receiving these briefs, please send an email to: info@section27.org.za. And please share widely with others you think might be interested.
Good Governance for Medicines in JordanMeTApresents
Presentation by the Director General, Jordan Food and Drug Administration (JFDA) on ' Good Governance for Medicines in Jordan', during the World Health Assembly (WHA) in Geneva, 19 May 2009.
This presentation by the US Federal Trade Commission was made during a workshop on “Regulation and competition in light of digitalisation” held by the OECD in Paris on 31 January 2018. More papers and presentations on the topic can be found out at oe.cd/wrcd.
Interventions that fail to sustain: Evidence from a training and certificatio...ILRI
Poster by Charity Kinyua, Silvia Alonso, Emma Blackmore and Vusilizwe Thebe presented at the virtual Agriculture, Nutrition and Health (ANH) Academy Week 2021, 29 June – 1 July 2021.
Presentation by Dennis Ross-Degnan on tools and approaches that can be used by countries involved in the Medicines Transparency Alliance (MeTA), at the London launch in May 2008
MeTA: Overview and lessons learned in pilot countriesMeTApresents
Presentation on MeTA, overview and lessons learned in pilot countries by MeTA's Executive Director, during the World Health Assembly (WHA), Geneva on19 May 2009.
MeTA: Overview and lessons learned in pilot countriesMeTApresents
Presentation on MeTA overview and lessons learned in pilot countries by Brian Elliot, Executive Director, MeTA, during the World Health Assembly (WHA), Geneva on 19 May 2009.
Presentation on MeTA Jordan by the Chairman, MeTA Council & Secretary General, High Health Council, during the World Health Assembly (WHA), Geneva on 19 May 2009.
Presentation delivered by Dr Adham Ismail, Regional Adviser, Health Technologies at the 62nd Session of the WHO Regional Committee for the Eastern Mediterranean
Presentation in the framework of the International Conference "10th anniversary of the Spanish Network of Health Technology Assessment Agencies. Towads patient and public engagement in HTA" Zaragoza 27-28 April 2017
The Future of Transparency: Five Pillars for Global Successpharmacertify
In this webcast, PharmaCertify™, a division of NXLevel Solutions, teams with Berkeley Research Group to share practical approaches to help you navigate the complexities of US and global transparency reporting. You will get concrete, actionable advice on how your company can stay on top of global transparency challenges and:
- Ensure that your transparency processes are scalable and aligned to business practices
- Be prepared for mergers and integrations
- Boost the effectiveness of your data review process
- Manage TOV pre-disclosure
- Maximize your communication and education efforts
Speakers:
Pete Sandford, EVP, NXLevel Solutions
Mr. Sandford is the Executive Vice President and co-founder of NXLevel Solutions. He is a highly-regarded leader in the life sciences training industry and his experience in the field dates back nearly 25 years. Peter has been published in a number of industry journals and he has spoken extensively on the topic of effective and engaging training for the life sciences industry.
Katherine Norris, Director, Berkeley Research Group
Ms. Norris supports life sciences companies in a broad range of strategic and operation compliance objectives. As an industry professional, Ms. Norris has developed and overseen all aspects of compliance programs, including CIA implementation, global and domestic Aggregate Spend, HCP interactions, clinical post-market surveillance and general compliance.
Sets out the five core principles which guide the operation of the Medicines Transparency Alliance (MeTA) in efforts to increase transparency, accountability and governance around the supply of essential medicines.
MeTA pilot countries support needs and recommendationsMeTApresents
An overview of MeTA pilot countries support needs and recommendations, a presentation by Elodie Brandamir, MeTA Operations Director during the MeTA countries sharing meeting, London 2009
Presentation on Concept and structure of MeTA by Wilbert Bannenberg, MeTA Technical Director during the MeTA Country Sharing Meeting, London, 8 December 2009.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
6. Basic Strategy 06/04/09 MeTA Multi-stakeholder Collaboration Sharing Responsibility, Achieving as One through
7. Building MeTA in the Philippines December 2007 Induction of Officers, & First National Multi-Stakeholder Forum (Launch) November, 2007 Election of Officers July to September, 2007 Invitation and enlisting of prospective members May to July, 2007 Technical Working Group Meetings to form MeTA Structure April 2007 Scoping Visit
11. How do we work? MeTA Council Administrative Committee Technical Committee Research and Assessments Secretariat and In- Country Coordinator (WHO Country Office ) MeTA Forum
12.
13.
14.
15. Integrating MeTA Support into Local reforms Health Reforms: FOURmula I for Health (F1) Service delivery Financing Regulations Good Governance MeTA Transparency and Good Governance Assessment and Technical Support Systems for proper resource management and building sustainable financing models Improved access and support to decentralized systems
![06/04/09 MeTA Introduction ,[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)